Fundamental Analysis of Biomarin Pharmaceutical Inc - Growth / Value Index
BMRN - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 67.19
Undervalued - Price to Intrinsic Value of 0.0003
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 20.93 | 101.07 | -2.37 % | |
| Price to Book | 1.94 | 3.00 | -5.74 % | 3.05 |
| Price to Sales | 2.12 | 6.43 | -8.02 % | |
| Enterprise Value to EBITDA Multiple | 0.087 | 57.68 | -36.40 % |
BMRN - Profitability Highlights
Profitability Analysis
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
Reasonable Dividend Yield of 3.71 %
EBITDA is continuously increasing for last 3 Years
Good Net Margin of 10.14% is achieved by the company
Low Earning Yield of 4.65 %
In the last three years, the company has given poor Returns on Equity
In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 9.27 | 2.97 | -3.45 % | 1.75 |
| Return On Asset | 6.78 | 2.15 | -3.23 % | 1.29 |
| Net Profit Margin | 10.14 | 6.36 | -5.79 % | 13.66 |
| Operating Profit Margin | 9.47 | 5.19 | -27.27 % | 13.63 |
| EBITDA Margin | 9.48 | 11.40 | 44.23 % | 13.63 |
Highlights
| Market Cap | 14727.09 M |
| Enterprise Value | 15058.94 M |
| Price/Book TTM | 1.94 |
| Outstanding Share | 189880 K |
| Float/ Outstanding Share | 99.23% |
| Dividend Yield | 3.71 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.67 |
| Peter Lynch Ratio | 0.118 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 5.27 |
| Sloan Ratio | 0.0012 |
| Peter Lynch Fair Value | 92.62 |
BMRN - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 1826.08 B | 10.23 % | 100306 % |
| Gross Profit | 1447.94 B | 11.88 % | 102430 % |
| EBITDA | 173034 M | 58.99 % | 215240 % |
| Net Profit | 185100 M | 3.86 % | 435050 % |
| EPS | 3.70 | 2.43 % | NA |
BMRN - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 65.62
Altman Z Score of 5.40 suggests good Stability
Debt to equity ratio has decreased and is lowest in last five years
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.220 | -7.58 % | 0.098 |
| Cash Ratio | 0.912 | -58.40 % | |
| Quick Ratio | 1.57 | -50.20 % | 1.70 |
| Shareholders Equity | 72.37 | 0.233 % | |
| Debt to EBITDA | 4.13 | -37.47 % |
Historical Valuation Ratios of Biomarin Pharmaceutical Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Biomarin Pharmaceutical Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Biomarin Pharmaceutical Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Biomarin Pharmaceutical Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)